Longevica company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

longevica.com

Stage

Unattributed VC | Alive

Total Raised

$3M

Last Raised

$2.5M | 6 mos ago

About Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

Longevica Headquarter Location

7 Deerpark Drive

Monmouth Junction, New Jersey, 08852,

United States

732-230-3169

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Longevica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Longevica is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Longevica Patents

Longevica has filed 5 patents.

The 3 most popular patent topics include:

  • Chelating agents
  • Transcription factors
  • Health insurance
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/18/2017

5/19/2020

Chelating agents, Enzymes, Metabolism, Gastrointestinal tract disorders, EC 2.1.1

Grant

Application Date

10/18/2017

Grant Date

5/19/2020

Title

Related Topics

Chelating agents, Enzymes, Metabolism, Gastrointestinal tract disorders, EC 2.1.1

Status

Grant

Latest Longevica News

As startups flood the longevity space, bioniq launches hyper-personalised supplements – TechCrunch

Feb 9, 2022

Last year we covered Longevica, which had raised $13 million after researching supplements to increase human longevity.Now, London-based bioniq, which has raised $15 million in VC from OKS Group and Medsi Group, says it is launching ‘bioniq GO’, a “personalised supplements product that relies on 3 million proprietary biochemical data points”.The implications of this trend is that startups like bioniq and Longevica are basically starting to get into the realms of longevity using big data around these so-called ‘age-defying’ chemicals.Bioniq and Longevica are not the only startup in this space.New wellness startup Heights raised a $2 million Seed funding round (£1.7M) via the Seedrs crowdfunding platform, last year. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.

Longevica Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Longevica Rank

  • Where is Longevica's headquarters?

    Longevica's headquarters is located at 7 Deerpark Drive, Monmouth Junction.

  • What is Longevica's latest funding round?

    Longevica's latest funding round is Unattributed VC.

  • How much did Longevica raise?

    Longevica raised a total of $3M.

  • Who are the investors of Longevica?

    Investors of Longevica include Xploration Capital, Foundation Venture Capital Group and Alexander Chikunov.

  • Who are Longevica's competitors?

    Competitors of Longevica include Cerecin, Acumen Pharmaceuticals, Cyclacel Pharmaceuticals, Philogen, Endocyte, Innate Pharma, Aerie Pharmaceuticals, BaroFold, Biosceptre International, Threshold Pharmaceuticals and 42 more.

You May Also Like

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

A
Anaborex

Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.

ARC Pharmaceuticals Logo
ARC Pharmaceuticals

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.

P
Panacea Pharmaceuticals

Panacea Pharmaceuticals, founded in 1999, discovers, develops, and commercializes novel therapeutic and diagnostic products for oncology and diseases of the central nervous system. Since its inception, the Company's primary approach to cancer treatment has been immunotherapy and development of companion diagnostics for comprehensive patient management. The Company's lead drug product candidate is a nanoparticle-based therapeutic cancer vaccine that targets a novel patented tumor marker, human aspartyl (asparaginyl) -hydroxylase (HAAH).

Immunservice Logo
Immunservice

Immunservice is a biopharmaceutical company addressing orphan disease indications as well as large market indication areas, especially those of high unmet medical need.Immunservice's biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.Biomimetic therapy has the clear potential to cure patients with cancer, even those who are in urgent need and have little or no treatment alternatives.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.